SMMT Q2 2023 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$235,000+0.0% YoY

Gross Profit

-$236,000-100.4% margin

Operating Income

-$16M-6720.9% margin

Net Income

-$15M-6262.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$237M

Total Liabilities

$118M

Stockholders' Equity

$120M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$235,000	$235,000	+0.0%
Gross Profit	-$236,000	$193,054	-222.2%
Operating Income	-$16M	-$13M	-24.4%
Net Income	-$15M	-$17M	+12.2%